TG Therapeutics, Inc. (TGTX) stock analysis
In our weekly check, TG Therapeutics, Inc. is graded C (A to F). Of 23 checks on debt, profit, cash flow and trend: 15 pass, warnings: 4, red flags: 4.
About TG Therapeutics, Inc.
TG Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as TGTX.
What our checks show for TGTX
Red flags
- The gross margin fell by 5.4 points, to 82.7%: costs are rising faster than prices.
- The stock has fallen as much as 100% from a peak. Would you have held through that?
- Beta 1.81: the stock usually moves more than the market, both up and down.
- Pay in shares equals 103% of free cash flow: it dilutes shareholders.
Warning signs
- Debt is high against equity (1.32x), although net debt is 1.7x a year of EBITDA. That limits room in a downturn.
- Earnings per share fell 20.1% a year over the last 3 years.
- The price swings a lot: 45% annual volatility. Expect large ups and downs.
- The stock is still below its previous peak.
Strengths
- The net margin rose by 5216 points over 5 years, to 11.8%.
- Analysts expect earnings per share to grow about 104% a year over the next years.
- Analysts expect revenue to grow about 29.4% a year over the next years.
- Analysts expect the net margin to improve by 21 points from today's 11.8%.
- Revenue grew 586% a year over the last 3 years.
Similar companies
SYRE · MDGL · PCVX · PRAX · KRYS · KYMR
Questions
What grade does TG Therapeutics, Inc. (TGTX) have?
In our weekly check, TG Therapeutics, Inc. is graded C (A to F). Of 23 checks on debt, profit, cash flow and trend: 15 pass, warnings: 4, red flags: 4. The grade is a risk check, not a buy or sell recommendation.
What are the main risks of TGTX stock?
This week's biggest flags for TG Therapeutics, Inc.: Gross margin falling, Deep past fall, High beta. In total 8 of 23 checks show a warning or a red flag.
What does TG Therapeutics, Inc. do?
TG Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as TGTX.
The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.
Updated 2026-11-14
Open the full analysis